Cel-Sci Corp., of Vienna, Va., said the institutional review board of the U.S. Navy’s Naval Medical Center, of San Diego, approved the start of a Phase I dose-escalation study of immunotherapy Multikine (leukocyte interleukin, injection) in HIV/human papillomavirus co-infected men and women with perianal warts.